Literature DB >> 7026903

Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia.

K F Bradstock, G Janossy, N Tidman, E S Papageorgiou, H G Prentice, M Willoughby, A V Hoffbrand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7026903     DOI： 10.1016/0145-2126(81)90002-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  15 in total

Review 1.  A 50-year journey to cure childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

Review 2.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 3.  Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Authors:  Dario Campana; Ching-Hon Pui
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

Review 4.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

5.  Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Authors:  Elisabeth Paietta
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

Review 6.  Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.

Authors:  Renato Bassan; Orietta Spinelli
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 7.  Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Authors:  Elaine Coustan-Smith; Dario Campana
Journal:  Best Pract Res Clin Haematol       Date:  2010-10-28       Impact factor: 3.020

Review 8.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 9.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

Review 10.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.